KPV 10mg/Vial Structural & Preclinical Research Guide

Overview of KPV 10mg/Vial in Preclinical Research

KPV 10mg/vial contains a lyophilized tripeptide (Lys-Pro-Val) derived from the C-terminal sequence of alpha-melanocyte-stimulating hormone. It is a research compound studied in laboratory settings for its capacity to inhibit NF-κB activation, reduce pro-inflammatory cytokine expression, and preserve epithelial barrier integrity in mucosal and cutaneous inflammation models.

Unlike larger peptide structures that present formulation challenges or rapid degradation in enzymatic environments, the tripeptide sequence Lysine-Proline-Valine exhibits unique pharmacokinetic characteristics in experimental models. Research laboratories routinely utilize the KPV 10mg product to investigate localized intracellular signaling without inducing the melanogenic systemic responses associated with full-length melanocortin receptor agonists.

In vitro and animal model data indicate that KPV operates primarily through non-receptor-mediated intracellular mechanisms or specialized transport systems such as PepT1, making it a critical tool for mapping inflammatory cascades in complex tissues.

Molecular Structure and Derivation from Alpha-MSH

KPV represents amino acids 11 through 13 of alpha-melanocyte-stimulating hormone (α-MSH). Chemically designated as L-lysyl-L-prolyl-L-valine, this tripeptide possesses a molecular weight of approximately 383.48 g/mol. Covalent cleavage of α-MSH isolates the tripeptide responsible for a substantial portion of the parent molecule's anti-inflammatory activity, while omitting the sequences responsible for pigmentary changes mediated via melanocortin-1 receptors (MC1R).

The presence of the proline residue provides rigid conformational constraints that stabilize the peptide backbone against rapid enzymatic cleavage by carboxypeptidases in cellular culture media. Laboratory investigations into alpha-MSH signaling mechanisms frequently compare the full-length hormone against KPV to isolate localized immune modulation from receptor-driven systemic responses.

Because of its small molecular footprint, KPV exhibits rapid cellular uptake in transport assays. Studies demonstrate that the tripeptide can enter epithelial cells directly via the oligopeptide transporter PepT1 (SLC15A1), which is frequently upregulated in inflamed intestinal mucosal tissues.

Mechanism of Action: NF-κB Pathway Modulation

The primary mechanism of action documented for KPV across preclinical literature is the downregulation of nuclear factor kappa B (NF-κB) transcription factor activity. In resting cells, NF-κB resides in the cytoplasm bound to inhibitory IκB proteins. Upon stimulation by inflammatory signals such as tumor necrosis factor-alpha (TNF-α) or lipopolysaccharide (LPS), IκB undergoes phosphorylation and degradation, allowing NF-κB to translocate into the nucleus and initiate transcription of pro-inflammatory cytokines.

In vitro assays indicate that KPV penetrates the cell membrane and directly interacts with intracellular target proteins to prevent the nuclear translocation of the NF-κB p65 subunit. By blocking this nuclear import step, KPV suppresses the expression of downstream inflammatory mediators, including IL-1β, IL-6, IL-8, and TNF-α.

Furthermore, preclinical research suggests KPV can enter the cell nucleus to directly attenuate NF-κB binding to promoter regions on DNA. This dual mechanism—inhibiting nuclear entry and interrupting DNA binding—renders KPV a potent focal molecule for investigating acute and chronic inflammatory responses.

Intestinal Barrier Function and Colitis Preclinical Literature

A major area of KPV research centers on gastrointestinal physiology and mucosal immunology. In rodent models of dextran sulfate sodium (DSS)-induced colitis and 2,4,6-trinitrobenzene sulfonic acid (TNBS)-induced colitis, researchers have evaluated KPV's capacity to attenuate tissue damage and restore tight junction integrity.

Preclinical data show that KPV treatment in enteric models reduces leukocyte infiltration, lowers myeloperoxidase (MPO) activity, and attenuates histological lesions in intestinal tissue samples. At the cellular level, KPV preserves the expression and membrane localization of key tight junction proteins, including zonula occludens-1 (ZO-1) and occludin, which are crucial for maintaining mucosal barrier resistance.

Innovative drug delivery studies have utilized hyaluronic acid-functionalized nanoparticles loading KPV to target inflamed intestinal epithelium specifically via CD44 receptor endocytosis. These targeted delivery models demonstrate enhanced local tissue concentrations and reduced systemic clearance, validating KPV as a candidate for advanced drug delivery research.

Dermatological and Systemic Anti-Inflammatory Assays

In addition to gastrointestinal models, KPV has been extensively investigated in cutaneous inflammation research. In vitro assays utilizing human keratinocytes (HaCaT cells) and dermal fibroblasts demonstrate that KPV reduces UVB-induced IL-8 secretion and cellular apoptosis.

Animal studies evaluating contact hypersensitivity and allergic dermatitis show that topical or localized application of KPV attenuates edema, reduces swelling, and suppresses the accumulation of pro-inflammatory dendritic cells and T lymphocytes in dermal tissues. The tripeptide exhibits similar efficacy to broader-spectrum anti-inflammatory agents in these models, but without inducing local tissue atrophy.

Beyond cytokine suppression, preclinical literature highlights a secondary antimicrobial effect inherent to KPV. In microbiological assays, KPV demonstrated direct growth inhibition against *Candida albicans* and *Staphylococcus aureus* at micromolar concentrations, driven by membrane-disruptive biophysical interactions unique to its cationic lysine residue.

Comparative Peptide Profiling: KPV vs. Related Inflammation Research Compounds

To properly position KPV within a experimental design, laboratory researchers frequently compare its activity profile against other well-characterized regulatory peptides operating in mucosal and tissue repair pathways.

While KPV targets the intracellular NF-κB pathway directly to downregulate cytokine synthesis, compounds like BPC-157 5mg operate primarily through growth factor modulation, nitric oxide pathway regulation, and VEGFR2-mediated angiogenesis. In contrast, Larazotide acetate functions as a synthetic tight junction regulator that acts externally as a zonulin antagonist to prevent junction disassembly, rather than altering intracellular transcription factor translocation. Meanwhile, antimicrobial host-defense peptides such as LL-37 peptide prioritize direct bacterial membrane permeabilization and immune cell recruitment over direct NF-κB nuclear import blockades. Comparing these mechanisms allows researchers to select the precise molecular pathway required for their specific tissue or cellular model.

Laboratory Handling, Reconstitution, and Storage Specifications

KPV is supplied as a lyophilized powder containing 10mg of pure tripeptide sequence per vial. To preserve chemical stability, unopened vials should be stored in a freezer at -20°C or -80°C upon receipt, protected from light and moisture.

For reconstitution in laboratory settings, researchers should allow the vial to equilibrate to room temperature before opening to prevent atmospheric condensation. Reconstitution should be performed using sterile, endotoxin-free water or phosphate-buffered saline (PBS, pH 7.4). For applications requiring extended storage after liquid preparation, sterile bacteriostatic water (0.9% benzyl alcohol) may be used.

A standard reconstitution protocol involves adding 2.0 mL of diluent to yield a working stock concentration of 5.0 mg/mL (13.04 mM). Gently swirl or invert the vial until complete dissolution occurs; avoid vigorous vortexing, which can introduce shear stress or foam. Once reconstituted, stock solutions should be aliquoted into single-use microcentrifuge tubes and stored at -20°C or -80°C to minimize freeze-thaw cycles, which degrade peptide integrity over time.

Analytical Quality Assurance: HPLC, MS, and Endotoxin Testing

Rigorous research requires chemical purity and consistency across experimental lots. PX1 Research subjects every production lot of KPV to stringent analytical characterization before release.

Purity is quantitatively determined using Reverse-Phase High-Performance Liquid Chromatography (RP-HPLC). High-grade KPV must demonstrate a single sharp peak with greater than 98% area under the curve (AUC), ensuring the absence of truncated sequences, truncated deletion peptides, or residual synthesis reagents.

Molecular identity is confirmed via Electrospray Ionization Mass Spectrometry (ESI-MS), verifying the monoisotopic mass of the KPV molecule (383.48 g/mol). Additionally, because KPV is frequently deployed in sensitive cell culture and animal models of inflammation, endotoxin levels are measured via Limulus Amebocyte Lysate (LAL) testing to ensure levels remain strictly under 0.05 EU/mg. Researchers can review lot-specific analytical data directly via our third-party COA verification platform.

Supply Chain Integrity & Domestic Manufacturing Standards

The reliability of in vitro and in vivo data depends on consistent material sourcing. Substandard or imported peptides often suffer from residual counter-ion contamination, batch-to-batch variability, or incorrect peptide content assays.

All peptides supplied by PX1 Research are manufactured in state-of-the-art facilities compliant with current Good Manufacturing Practices (cGMP) within the United States. Quality testing is performed by independent ISO 17025 accredited analytical laboratories.

To support high-throughput research laboratories and institutional procurement, PX1 maintains a transparent supply chain with full lot traceability. Orders ship directly from fulfillment centers in California and Arizona with same-day processing for orders placed Monday through Friday before cut-off times. Institutional buyers can apply for dedicated institutional terms through our wholesale lab accounts portal, or browse our full range of compounds through our catalog of all research peptides.

In Vitro Assay Protocols & End-Point Measurement Metrics

When designing experiments with KPV 10mg/vial, researchers typically employ dose-response concentrations ranging from 10 nM to 100 μM in cell culture media, depending on the cell line and inflammatory stimulus used.

In intestinal epithelial cell lines (such as Caco-2 or HT-29 monolayers grown on Transwell inserts), key end-point metrics include measuring Transepithelial Electrical Resistance (TEER) following stimulation with TNF-α or IFN-γ. Addition of KPV to the apical or basolateral chamber allows quantification of barrier recovery.

Molecular end-points are evaluated using quantitative Real-Time PCR (qPCR) to measure changes in mRNA expression for IL-6, IL-1β, and COX-2. Western blot analysis of nuclear vs. cytoplasmic fractions is commonly performed to quantify p65 nuclear translocation, while immunofluorescence microscopy visualizes the spatial distribution of ZO-1 and occludin tight junction networks.